Suzhou Baimai Biopharmaceutical
Innovative drug research and development platform for "new generation tumor immunotherapy technology".
Market cap
-
Enterprise valuation
$11—17m (Dealroom.co estimates Dec 2022.)
China (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
* | CNY20.0m | Series A | |
* | CNY20.0m | Series A | |
Total Funding | $5.5m |